Indira Guleria

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2692656/publications.pdf

Version: 2024-02-01

52	4,928	29 h-index	48
papers	citations		g-index
53	53	53	7487
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Tissue expression of PD-L1 mediates peripheral T cell tolerance. Journal of Experimental Medicine, 2006, 203, 883-895.	8.5	1,042
2	A critical role for the programmed death ligand 1 in fetomaternal tolerance. Journal of Experimental Medicine, 2005, 202, 231-237.	8.5	375
3	Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3 ⁺ CD4 ⁺ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9331-9336.	7.1	348
4	Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway. Journal of Experimental Medicine, 2006, 203, 2737-2747.	8.5	280
5	Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6682-6687.	7.1	266
6	Maternal Acceptance of the Fetus: True Human Tolerance. Journal of Immunology, 2007, 178, 3345-3351.	0.8	222
7	The trophoblast is a component of the innate immune system during pregnancy. Nature Medicine, 2000, 6, 589-593.	30.7	200
8	Auxotrophic vaccines for tuberculosis. Nature Medicine, 1996, 2, 334-337.	30.7	166
9	The Combination of Donor and Recipient Age is Critical in Determining Host Immunoresponsiveness and Renal Transplant Outcome. Annals of Surgery, 2010, 252, 662-674.	4.2	165
10	The Link between the PDL1 Costimulatory Pathway and Th17 in Fetomaternal Tolerance. Journal of Immunology, 2011, 187, 4530-4541.	0.8	145
11	Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism― New England Journal of Medicine, 2016, 375, 196-198.	27.0	138
12	A Link between PDL1 and T Regulatory Cells in Fetomaternal Tolerance. Journal of Immunology, 2007, 179, 5211-5219.	0.8	136
13	Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes. Diabetes, 2008, 57, 3013-3024.	0.6	126
14	Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2006, 176, 3480-3489.	0.8	122
15	Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clinical Immunology, 2007, 125, 16-25.	3.2	111
16	TIM-3 Regulates Innate Immune Cells To Induce Fetomaternal Tolerance. Journal of Immunology, 2013, 190, 88-96.	0.8	92
17	Critical Role of Donor Tissue Expression of Programmed Death Ligand-1 in Regulating Cardiac Allograft Rejection and Vasculopathy. Circulation, 2008, 117, 660-669.	1.6	89
18	Aberrant Macrophage and Neutrophil Population Dynamics and Impaired Th1 Response to Listeria monocytogenesin Colony-Stimulating Factor 1-Deficient Mice. Infection and Immunity, 2001, 69, 1795-1807.	2.2	71

#	Article	IF	Citations
19	Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: The V-HEALTH study. Journal of Vascular Surgery, 2009, 50, 1359-1368.e1.	1.1	71
20	Impact of Pretransplant Anti-HLA Antibodies on Outcomes in Lung Transplant Candidates. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1234-1239.	5.6	65
21	Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. Journal of Clinical Investigation, 2020, 130, 4624-4636.	8.2	55
22	Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes. PLoS ONE, 2014, 9, e89561.	2.5	54
23	Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature, 2021, 590, 157-162.	27.8	53
24	Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clinical Immunology, 2008, 126, 140-147.	3.2	52
25	Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis. Clinical Immunology, 2012, 142, 351-361.	3.2	50
26	Targeting antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity. JCI Insight, 2018, 3, .	5.0	48
27	Role of PD1/PDL1 pathway, and TH17 and treg cells in maternal tolerance to the fetus. Biomedical Journal, 2015, 38, 25.	3.1	47
28	A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood, 2018, 132, 1911-1921.	1.4	44
29	Ischemia augments alloimmune injury through IL-6-driven CD4+ alloreactivity. Scientific Reports, 2018, 8, 2461.	3.3	42
30	B7h (ICOS-L) Maintains Tolerance at the Fetomaternal Interface. American Journal of Pathology, 2013, 182, 2204-2213.	3.8	30
31	Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation. PLoS ONE, 2016, 11, e0162409.	2.5	30
32	Repetitive ischemic injuries to the kidneys result in lymph node fibrosis and impaired healing. JCI Insight, 2018, 3, .	5.0	29
33	Dendritic Cells in Kidney Transplant Biopsy Samples Are Associated with T Cell Infiltration and Poor Allograft Survival. Journal of the American Society of Nephrology: JASN, 2015, 26, 3102-3113.	6.1	28
34	In vivo depletion of CD4 and CD8 T lymphocytes impairs Mycobacterium w vaccine-induced protection against M. tubercolosis in mice. Medical Microbiology and Immunology, 1993, 182, 129-35.	4.8	25
35	Glomerular Inflammation Correlates With Endothelial Injury and With IL-6 and IL- $1\hat{l}^2$ Secretion in the Peripheral Blood. Transplantation, 2014, 97, 1034-1042.	1.0	24
36	Divergent Role of Donor Dendritic Cells in Rejection versus Tolerance of Allografts. Journal of the American Society of Nephrology: JASN, 2009, 20, 535-544.	6.1	20

#	Article	IF	Citations
37	Effect of TIM-3 Blockade on the Immunophenotype and Cytokine Profile of Murine Uterine NK Cells. PLoS ONE, 2015, 10, e0123439.	2.5	16
38	The Presence of Pretransplant HLA Antibodies Does Not Impact the Development of Chronic Lung Allograft Dysfunction or CLAD-Related Death. Transplantation, 2017, 101, 2207-2212.	1.0	14
39	Antibodies against HLA-DP recognize broadly expressed epitopes. Human Immunology, 2016, 77, 1128-1139.	2.4	10
40	Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney Transplantation. Transplantation Direct, 2019, 5, e446.	1.6	5
41	The impact of screening method on HLA antibody detection before and after lung transplantation: A prospective pilot study. Journal of Heart and Lung Transplantation, 2018, 37, 531-533.	0.6	4
42	Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade. Cancer Immunology, Immunotherapy, 2019, 68, 1331-1340.	4.2	3
43	Biomarkers in Fetomaternal Tolerance. Clinics in Laboratory Medicine, 2019, 39, 145-156.	1.4	3
44	How do I: Evaluate the safety and legitimacy of unproven cellular therapies?. Transfusion, 2022, 62, 518-532.	1.6	3
45	Infection With <i>Listeria monocytogenes</i> as a Probe for Placental Immunological Function. , 2006, 122, 435-442.		2
46	Anti-CD3 mAb treatment cures PDL1â^'/â^'.NOD mice of diabetes but precipitates fatal myocarditis. Clinical Immunology, 2011, 140, 47-53.	3.2	2
47	Divergent Function of Programmed Death-Ligand 1 in Donor Tissue versus Recipient Immune System in a Murine Model of Bronchiolitis Obliterans. American Journal of Pathology, 2017, 187, 1368-1379.	3.8	2
48	Presence of Anti-HLA Antibodies at High Threshold in Patients Listed for Lung Transplantation Is Associated With a Lower Transplant Rate and a Higher Antibody Mediated Rejection Incidence Posttransplant. Chest, 2013, 144, 1015A.	0.8	1
49	Development of a Calculated Panel Reactive Antibody Web Service with Local Frequencies for Platelet Transfusion Refractoriness Risk Stratification. Journal of Pathology Informatics, 2019, 10, 26.	1.7	1
50	Induced costimulatory molecule-B7h costimulatory pathway in alloimmune regulation. Current Opinion in Organ Transplantation, 2005, 10, 186-190.	1.6	0
51	Preface. Clinics in Laboratory Medicine, 2019, 39, xiii-xiv.	1.4	0
52	Immunoregulation at the fetomaternal interface. Human Immunology, 2021, 82, 315-316.	2.4	0